Cheryl Li

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

K. Kannan, R. Gregory, M. Levis, 2022, Haematologica.

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer

Xiaoying Chen, R. Ewesuedo, D. Yin, 2019, Cancer Chemotherapy and Pharmacology.